Olmesartan medoxomil and Hyperlipidaemia - a phase IV clinical study of FDA data

Summary:

Hyperlipidaemia is reported as a side effect among people who take Olmesartan medoxomil (olmesartan medoxomil), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Lipitor, and have Castleman's disease.

The phase IV clinical study analyzes which people have Hyperlipidaemia when taking Olmesartan medoxomil. It is created by eHealthMe based on reports of 14,970 people who have side effects when taking Olmesartan medoxomil from the FDA, and is updated regularly.

What is Olmesartan medoxomil?

Olmesartan medoxomil has active ingredients of olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 15,240 Olmesartan medoxomil users. Check the latest studies of Olmesartan medoxomil.

What is Hyperlipidaemia?

Hyperlipidaemia (presence of excess lipids in the blood) is found to be associated with 1,422 drugs and 1,410 conditions by eHealthMe. Check the latest studies of Hyperlipidaemia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

14,970 people reported to have side effects when taking Olmesartan medoxomil.
Among them, 23 people (0.15%) have Hyperlipidaemia.

Could Olmesartan medoxomil cause Hyperlipidaemia?

Among these 23 people:

How long have people been on Olmesartan medoxomil when they have Hyperlipidaemia? *

What is the gender of people who have Hyperlipidaemia when taking Olmesartan medoxomil? *

female: 40 %
male: 60 %

What is the age of people who have Hyperlipidaemia when taking Olmesartan medoxomil? *

What are other drugs people take besides Olmesartan medoxomil? *

What are other side effects people have besides Hyperlipidaemia? *

Anaemia (lack of blood): 8 people, 34.78%
Weight Loss: 5 people, 21.74%
Rickets (softening of bones): 4 people, 17.39%
Headache (pain in head): 4 people, 17.39%
Mood Swings (an extreme or rapid change in mood): 3 people, 13.04%
Blood Iron Decreased: 3 people, 13.04%
Back Pain: 3 people, 13.04%
Blockage Of Leg Arteries: 3 people, 13.04%
Mental Status Changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation): 3 people, 13.04%
Memory Loss: 3 people, 13.04%

What are the existing conditions these people have? *

Castleman's Disease (a disease of lymph nodes and related tissues): 3 people, 13.04%
Stress And Anxiety: 2 people, 8.70%
Diabetes: 2 people, 8.70%
Pain: 2 people, 8.70%
Lupus Nephritis (a chronic inflammatory autoimmune disorder that may affect kidney tissue): 2 people, 8.70%
Hepatocellular Carcinoma (liver cancer): 1 person, 4.35%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 1 person, 4.35%
Diarrhea: 1 person, 4.35%
Essential Hypertension (primary hypertension): 1 person, 4.35%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 4.35%

* Approximation only. Some reports may have incomplete information.

Do you take Olmesartan medoxomil and have Hyperlipidaemia?

- Check whether Hyperlipidaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Olmesartan medoxomil:

Olmesartan medoxomil (15,240 reports)

Hyperlipidaemia treatments and more:

Hyperlipidaemia (86,394 reports)

Browse all side effects of Olmesartan medoxomil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperlipidaemia:

Hyperlipidaemia (1,422 drugs)

Browse all the conditions that are associated with Hyperlipidaemia:

Hyperlipidaemia (1,410 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on olmesartan medoxomil (the active ingredients of Olmesartan medoxomil) and Olmesartan medoxomil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.